V3: HIV's switch-hitter

AIDS Research and Human Retroviruses

Volumn 21, Issue 2, 2005, Pages 171-189

  Hartley, Oliver ^a   Klasse, Per Johan ^b   Sattentau, Quentin J ^c   Moore, John P ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIGENICITY; BINDING SITE; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; MOLECULAR EVOLUTION; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; VACCINE PRODUCTION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

AIDS VACCINES; AMINO ACID SEQUENCE; BINDING SITES; CHEMOKINES; HIV ENVELOPE PROTEIN GP120; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RECEPTORS, HIV; TROPISM;

EID: 14844360667     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.171     Document Type: Review

References (235)

1. Weiss CD, Levy JA, and White JM: Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol 1990;64:5674-5677.
2. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-430.
3. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
4. Lu M, Blacklow SC, and Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-1082.
5. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, and Hendrickson WA: Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000;74:1961-1972.
6. Zhu P, Chertova E, Bess J, Jr., et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 2003; 100:15812-15817.
7. Desrosiers RC: Prospects for an AIDS vaccine. Nat Med 2004;10:221-223.
8. Yuste E, Reeves JD, Doms RW, and Desrosiers RC: Modulation of Env content in virions of simian immunodeficiency virus: Correlation with cell surface expression and virion infectivity. J Virol 2004;78:6775-6785.
9. Johnson WE, Sanford H, Schwall L, et al.: Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol 2003;77:9993-10003.
10. Wyatt R, Kwong PD, Desjardins E, et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-711.
11. Poignard P, Saphire EO, Parren PW, and Burton DR: gp120: Biologic aspects of structural features. Annu Rev Immunol 2001; 19:253-274.
12. Ugolini S, Mondor I, and Sattentau QJ: HIV-1 attachment: Another look. Trends Microbiol 1999;7:144-149.
13. Fortin JF, Cantin R, Bergeron MG, and Tremblay MJ: Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization. Virology 2000;268:493-503.
14. Turville S, Wilkinson J, Cameron P, Dable J, and Cunningham AL: The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J Leukoc Biol 2003;74:710-718.
15. Pohlmann S, Baribaud F, and Doms RW: DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol 2001;22: 643-646.
16. Weiss CD: HIV-1 gp41: mediator effusion and target for inhibition. AIDS Rev 2003;5:214-221.
17. Pierson TC, and Doms RW: HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003;281:1-27.
18. Gallo SA, Finnegan CM, Viard M, et al.: The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003;1614:36-50.
19. Moore JP, and Stevenson M: New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000; 1:40-49.
20. Clapham PR, and McKnight A: Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 2002;83: 1809-1829.
21. Leonard CK, Spellman MW, Riddle L, et al.: Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-10382.
22. Goudsmit J, Debouck C, Meloen RH, et al.: Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A 1988;85: 4478-4482.
23. Javaherian K, Langlois AJ, LaRosa GJ, et al.: Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990;250:1590-1593.
24. Leszczynski JF, and Rose GD: Loops in globular proteins: a novel category of secondary structure. Science 1986;234:849-855.
25. Pal M, and Dasgupta S: The nature of the turn in omega loops of proteins. Proteins 2003;51:591-606.
26. Ring CS, Kneller DG, Langridge R, and Cohen FE: Taxonomy and conformational analysis of loops in proteins. J Mol Biol 1992;224:685-699.
27. Fetrow JS: Omega loops: nonregular secondary structures significant in protein function and stability. Faseb J 1995;9:708-717.
28. Parren PW and Burton DR: The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001;77:195-262.
29. Parren PW, Moore JP, Burton DR, and Sattentau QJ: The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. Aids 1999;13 (Suppl A):S137-162.
30. Parren PW, Mondor I, Naniche D, et al.: Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998;72:3512-3519.
31. Klasse PJ, and Sattentau QJ: Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002;83:2091-2108.
32. Klasse PJ, and Moore JP: Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J Virol 1996;70:3668-3677.
33. Burton DR, Saphire EO, and Parren PW: A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 2001;260:109-143.
34. Poignard P, Moulard M, Golez E, et al.: Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 2003;77:353-365.
35. Rizzuto CD, and Sodroski JG: Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997;71:4847-4851.
36. Arthur LO, Bess JW, Jr., Sowder RC, 2nd, et al.: Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science 1992;258:1935-1938.
37. Leith JG, Clark DA, Matthews TJ, et al.: Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses. AIDS Res Hum Retroviruses 2003;19:957-965.
38. Vzorov AN, and Compans RW: Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization. J Virol 2000;74:8219-8225.
39. Spruth M, Stoiber H, Kacani L, Schonitzer D, and Dierich MP: Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. AIDS Res Hum Retroviruses 1999; 15:533-543.
40. Kwong PD, Doyle ML, Casper DJ, et al.: HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420:678-682.
41. Labrijn AF, Poignard P, Raja A, et al.: Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003:77:10557-10565.
42. Moulard M, Phogat SK, Shu Y, et al.: Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 2002;99:6913-6918.
43. Burton DR, Desrosiers RC, Doms RW, et al.: HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004;5:233-236.
44. Moore JP and Ho DD: HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. Aids 1995;9 Suppl A:S117-136.
45. Klausner RD, Fauci AS, Corey L, et al.: Medicine. The need for a global HIV vaccine enterprise. Science 2003;300:2036-2039.
46. Garber DA, Silvestri G, and Feinberg MB: Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004;4:397-413.
47. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
48. Richman DD, Wrin T, Little SJ, and Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003;100:4144-4149.
49. Larder B: Mechanisms of HIV-1 drug resistance. Aids 2001;15 Suppl 5:S27-34.
50. Back NK, Smit L, Schutten M, et al.: Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol 1993;67:6897-6902.
51. Nara PL, Smit L, Dunlop N, et al.: Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol 1990;64:3779-3791.
52. McKeating JA, Gow J, Goudsmit J, et al.: Characterization of HIV-1 neutralization escape mutants. Aids 1989;3:777-784.
53. McKnight A, Weiss RA, Shotton C, et al.: Change in tropism upon immune escape by human immunodeficiency virus. J Virol 1995;69:3167-3170.
54. Klasse PJ, McKeating JA, Schutten M, Reitz MS, Jr., and Robert-Guroff M: An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(→Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Virology 1993;196:332-337.
55. Zhang PF, Bouma P, Park EJ, et al.: A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 2002;76:644-655.
56. Pugach P, Kuhmann SE, Taylor J, et al.: The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 2004;321:8-22.
57. Baldinotti F, Matteucci D, Mazzetti P, et al.: Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol 1994; 68:4572-4579.
58. Cook RF, Berger SL, Rushlow KE, et al.: Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein. J Virol 1995;69:1493-1499.
59. Means RE, Greenough T, and Desrosiers RC: Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol 1997;71:7895-7902.
60. Montefiori DC, Reimann KA, Wyand MS, et al.: Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J Virol 1998;72:3427-3431.
61. Beaumont T, van Nuenen A, Broersen S, et al.: Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J Virol 2001;75:2246-2252.
62. di Marzo Veronese F, Reitz MS, Jr., Gupta G, et al.: Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. J Biol Chem 1993;268:25894-25901.
63. Beaumont T, Quakkelaar E, van Nuenen A, Pantophlet R, and Schuitemaker H: Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. J Virol 2004;78:5651-5657.
64. Platt EJ, Kozak SL, and Kabat D: Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000;16:871-882.
65. Moulard M, Lortat-Jacob H, Mondor I, et al.: Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000;74:1948-1960.
66. Mondor I, Ugolini S, and Sattentau QJ: Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 1998;72:3623-3634.
67. Zhang YJ, Hatziioannou T, Zang T, et al.: Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 2002;76:6332-6343.
68. Takeuchi Y, Akutsu M, Murayama K, Shimizu N, and Hoshino H: Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene. J Virol 1991;65:1710-1718.
69. Park EJ, Vujcic LK, Anand R, Theodore TS, and Quinnan G V, Jr: Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 1998;72:7099-7107.
70. Robert-Guroff M, Louie A, Myagkikh M, et al.: Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization. J Virol 1994;68:3459-3466.
71. Wilson C, Reitz MS, Jr., Aldrich K, et al.: The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J Virol 1990;64:3240-3248.
72. Thali M, Charles M, Furman C, et al.: Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol 1994;68:674-680.
73. Stern TL, Reitz MS, Jr., and Robert-Guroff M: Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions. J Virol 1995;69:1860-1867.
74. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science 1992;257:535-537.
75. Wyatt R, Thali M, Tilley S, et al.: Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J Virol 1992;66:6997-7004.
76. Sanders R W, Schiffner L, Master A, et al.: Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 2000;74:5091-5100.
77. Back NK, Smit L, De Jong JJ, et al.: An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994;199:431-438.
78. Sattentau QJ, and Moore JP: Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995;182:185-196.
79. Bou-Habib DC, Roderiquez G, Oravecz T, et al.: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
80. Fouts TR, Trkola A, Fung MS, and Moore JP: Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. AIDS Res Hum Retroviruses 1998;14:591-597.
81. Stamatatos L, Lim M, and Cheng-Mayer C: Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2000;16:981-994.
82. Moore JP, Cao Y, Qing L, et al.: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
83. Moore JP and Klasse PJ: Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation. AIDS Res Hum Retroviruses 1992;8:443-450.
84. Cavacini LA, Duval M, Robinson J, and Posner MR: Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. Aids 2002;16: 2409-2417.
85. Groenink M, Moore J P, Broersen S, and Schuitemaker H: Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. J Virol 1995;69:523-527.
86. O'Brien WA, Mao SH, Cao Y, and Moore JP: Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J Virol 1994; 68:5264-5269.
87. Moore JP, McKeating JA, Huang YX, Ashkenazi A, and Ho DD: Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992;66:235-243.
88. Karlsson GB, Gao F, Robinson J, Hahn B, and Sodroski J: Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J Virol 1996;70:6136-6142.
89. Edwards TG, Hoffman TL, Baribaud F, et al.: Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 2001;75:5230-5239.
90. Thomas ER, Shotton C, Weiss RA, Clapham PR, and McKnight A: CD4-dependent and CD4-independent HIV-2: Consequences for neutralization. Aids 2003;17:291-300.
91. Vodros D, Thorstensson R, Doms RW, Fenyo EM, and Reeves JD: Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques. Virology 2003;316:17-28.
92. Dehghani H, Puffer BA, Doms RW, and Hirsch VM: Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progresser macaques: association with CD4-independent usage of CCR5. J Virol 2003;77:6405-6418.
93. Lin G, Baribaud F, Romano J, Doms RW, and Hoxie JA: Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol 2003;77:931-942.
94. Lin G, Lee B, Haggarty BS, Doms RW, and Hoxie JA: CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain. J Virol 2001;75:10766-10778.
95. Moore JP, Kitchen SG, Pugach P, and Zack JA: The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004;20:111-126.
96. Douek DC: Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev 2003;5:172-177.
97. Wyatt R, Sullivan N, Thali M, et al.: Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 1993;67:4557-4565.
98. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
99. McKnight A, and Clapham PR: Immune escape and tropism of HIV. Trends Microbiol 1995;3:356-361.
100. O'Brien WA: Viral determinants of cellular tropism. Pathobiology 1992;60:225-233.
101. Burns DP, and Desrosiers RC: Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. Curr Top Microbiol Immunol 1994;188:185-219.
102. Hoffman TL, and Doms RW: HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol Membr Biol 1999;16:57-65.
103. Shioda T, Levy JA, and Cheng-Mayer C: Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1992;89:9434-9438.
104. Choe H, Farzan M, Sun Y, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
105. Cocchi F, DeVico AL, Garzino-Demo A, et al.: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996;2:1244-1247.
106. Shioda T, Oka S, Ida S, et al.: A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus. J Virol 1994;68:7689-7696.
107. Shimizu N, Haraguchi Y, Takeuchi Y, et al.: Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Virology 1999;259:324-333.
108. Pohlmann S, Davis C, Meister S, et al.: Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors. J Virol 2004;78:3223-3232.
109. Pastore C, Ramos A, and Mosier DE: Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 2004;78:7565-7574.
110. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
111. Jensen MA, Li FS, van 't Wout AB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77:13376-13388.
112. de Jong JJ, Goudsmit J, Keulen W, et al.: Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992;66:757-765.
113. Nabatov AA, Pollakis G, Linnemann T, et al.: Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 2004;78:524-530.
114. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659.
115. Pollakis G, Abebe A, Kliphuis A, et al.: Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 2004;78:2841-2852.
116. Brelot A, Heveker N, Adema K, et al.: Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 1999;73:2576-2586.
117. Pollakis G, Kang S, Kliphuis A, et al.: N-linked glycnsylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 2001;276:13433-13441.
118. Huang X, Barchi JJ, Jr., Lung FD, et al.: Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-IIIIB GP120 peptide RP135. Biochemistry 1997;36:10846-10856.
119. Malenbaum SE, Yang D, Cavacini L, et al.: The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol 2000;74:11008-11016.
120. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, and Mayer AJ: Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 1999;73:5294-5300.
121. Doranz BJ, Rucker J, Yi Y, et al.: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
122. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996;384:184-187.
123. Basmaciogullari S, Babcock GJ, Van Ryk D, Wojtowicz W, and Sodroski J: Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J Virol 2002;76:10791-10800.
124. Si Z, Gorry P, Babcock G, et al.: Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys. AIDS Res Hum Retroviruses 2004;20:163-173.
125. Sakaida H, Hori T, Yonezawa A, et al.: T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J Virol 1998;72:9763-9770.
126. Farzan M, Mirzabekov T, Kolchinsky P, et al.: Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999;96:667-676.
127. Bibollet-Ruche F, Gaof, Bailes E, et al. Complete genome analysis of one of the earliest SIV CPZPH strains from Gabon (SIVCPZGAB2). AIDS Res Hum Retrovirus 2004;20:1377-1381.
128. Rizzuto C, and Sodroski J: Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retroviruses 2000;16:741-749.
129. Marx PA, and Chen Z: The function of simian chemokine receptors in the replication of SIV. Semin Immunol 1998;10:215-223.
130. Otto C, Puffer BA, Pohlmann S, Doms RW, and Kirchhoff F: Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency. Virology 2003;315:292-302.
131. Edinger AL, Mankowski JL, Doranz BJ, et al.: CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci U S A 1997;94:14742-14747.
132. Reeves JD, Hibbitts S, Simmons G, et al.: Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 1999;73:7795-7804.
133. Dumonceaux J, Nisole S, Chanel C, et al.: Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 1998;72:512-519.
134. Hoffman TL, LaBranche CC, Zhang W, et al.: Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A 1999;96:6359-6364.
135. Kolchinsky P, Mirzabekov T, Farzan M, et al.: Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999;73:8120-8126.
136. Bhattacharya J, Peters PJ, and Clapham PR: CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. Aids 2003;17 Suppl 4:S35-43.
137. Kolchinsky P, Kiprilov E, and Sodroski J: Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001;75:2041-2050.
138. Puffer BA, Pohlmann S, Edinger AL, et al.: CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 2002;76:2595-2605.
139. Wang J, Babcock GJ, Choe H, et al.: N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. Virology 2004;324:140-150.
140. Chabot DJ, Chen H, Dimitrov DS, and Broder CC: N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J Virol 2000;74:4404-4413.
141. Hu Q, Trent JO, Tomaras GD, et al.: Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J Mol Biol 2000;302:359-375.
142. Cormier EG, Tran DN, Yukhayeva L, Olson WC, and Dragic T: Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol 2001;75:5541-5549.
143. Cormier EG and Dragic T: The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002;76:8953-8957.
144. Clark-Lewis I, Kim KS, Rajarathnam K, et al.: Structure-activity relationships of chemokines. J Leukoc Biol 1995;57:703-711.
145. Wells T, Proudfoot A, Power CA, et al.: The Molecular Basis of the Chemokine/Chemokine Receptor Interaction-Scope for Design of Chemokine Antagonists. Methods 1996;10:126-134.
146. Billick E, Seibert C, Pugach P, et al.: The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J Virol 2004;78:4134-4144.
147. Boyd MT, Simpson GR, Cann AJ, Johnson MA, and Weiss RA: A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 1993;67:3649-3652.
148. Ross TM, and Cullen BR: The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc Natl Acad Sci U S A 1998;95:7682-7686.
149. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, and Swanstrom R: Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002;76:3852-3864.
150. Bergeron L. Sullivan N, and Sodroski J: Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus. J Virol 1992;66:2389-2397.
151. Miller ED, Duus KM, Townsend M, et al.: Human immunodeficiency virus type 1 IIIB selected for replication in vivo exhibits increased envelope glycoproteins in virions without alteration in coreceptor usage: separation of in vivo replication from macrophage tropism. J Virol 2001;75:8498-8506.
152. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, and Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:2855-2864.
153. Gorry PR, Taylor J, Holm GH, et al.: Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol 2002;76: 6277-6292.
154. Peters PJ, Bhattacharya J, Hibbitts S, et al.: Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol 2004;78:6915-6926.
155. Rini JM, Stanfield RL, Stura EA, et al.: Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad Sci U S A 1993;90:6325-6329.
156. Ghiara JB, Ferguson DC, Satterthwait AC, Dyson HJ, and Wilson I: A Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. J Mol Biol 1997; 266:31-39.
157. Ghiara JB, Stura EA, Stanfield RL, Profy AT, and Wilson I: A Crystal structure of the principal neutralization site of HIV-1. Science 1994;264:82-85.
158. Stanfield RL, Ghiara JB, Ollmann Saphire E, Profy AT, and Wilson I: A Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. Virology 2003;315:159-173.
159. Stanfield R, Cabezas E, Satterthwait A, et al.: Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. Structure Fold Des 1999;7:131-142.
160. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, and Wilson IA: Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (Camb) 2004;12:193-204.
161. Sharon M, Kessler N, Levy R, et al.: Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb) 2003;11:225-236.
162. Moore JP, Thali M, Jameson BA, et al.: Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J Virol 1993;67:4785-4796.
163. Morrison HG, Kirchhoff F, and Desrosiers RC: Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry. Virology 1993;195:167-174.
164. Kwong PD, Wyatt R, Desjardins E, et al.: Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J Biol Chem 1999;274:4115-4123.
165. Catasti P, Bradbury EM, and Gupta G: Structure and polymorphism of HIV-1 third variable loops. J Biol Chem 1996;271: 8236-8242.
166. Catasti P, Fontenot JD, Bradbury EM, and Gupta G: Local and global structural properties of the HIV-MN V3 loop. J Biol Chem 1995;270:2224-2232.
167. Chandrasekhar K, Profy AT, and Dyson HJ: Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120. Biochemistry 1991;30:9187-9194.
168. de Lorimier R, Moody MA, Haynes BF, and Spicer LD: NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus. Biochemistry 1994;33: 2055-2062.
169. Gupta G, Anantharamaiah GM, Scott DR, Eldridge JH, and Myers G: Solution structure of the V3 loop of a Thailand HIV isolate. J Biomol Struct Dyn 1993;11:345-366.
170. Markert RL, Ruppach H, Gehring S, et al.: Secondary structural elements as a basis for antibody recognition in the immunodominant region of human immunodeficiency viruses 1 and 2. Eur J Biochem 1996;237:188-204.
171. Sarma AV, Raju TV, and Kunwar AC: NMR study of the peptide present in the principal neutralizing determinant (PND) of HIV-1 envelope glycoprotein gp120. J Biochem Biophys Methods 1997;34:83-98.
172. Vranken WF, Budesinsky M, Fant F, Boulez K, and Borremans FA: The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution. FEBS Lett 1995;374:117-121.
173. Vranken WF, Fant F, Budesinsky M, and Borremans FA: Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution. Eur J Biochem 2001;268:2620-2628.
174. Ding J, Smith AD, Geisler SC, et al.: Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1. Structure (Camb) 2002;10:999-1011.
175. Moore JP, and Doms RW: The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003;100: 10598-10602.
176. Kuhmann SE, Pugach P, Kunstman KJ, et al.: Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004;78:2790-2807.
177. Trkola A, Kuhmann SE, Strizki JM, et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002;99:395-400.
178. de Vreese K, Kofler-Mongold V, Leutgeb C, et al.: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 1996;70:689-696.
179. Reeves JD, Gallo SA, Ahmad N, et al.: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002;99:16249-16254.
180. Derdeyn CA, Decker JM, Sfakianos JN, et al.: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74:8358-8367.
181. Matthews T, Salgo M, Greenberg M, et al.: Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004;3:215-225.
182. Yuan W, Craig S, Si Z, Farzan M, and Sodroski J: CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol 2004; 78:5448-5457.
183. De Clercq E: The emerging role of fusion inhibitors in HIV infection. Drugs R D 1999;2:321-331.
184. Shattock RJ, and Moore JP: Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003;1:25-34.
185. Jagodzinski PP, Wustner J, Kmieciak D, et al.: Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes. Virology 1996;226:217-227.
186. Zolla-Pazner S: Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004;4:199-210.
187. Lusso P: Picking the lock with a hairpin. Did HIV-1 learn the art from chemokines? Structure (Camb) 2003;11:129-130.
188. Pakianathan DR, Kuta EG, Artis DR, Skelton NJ, and Hebert CA: Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 1997;36:9642-9648.
189. Nardese V, Longhi R, Polo S, et al.: Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat Struct Biol 2001;8:611-615.
190. Crump MP, Gong JH, Loetscher P, et al.: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. Embo J 1997;16:6996-7007.
191. Amara A, Lorthioir O, Valenzuela A, et al.: Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem 1999;274: 23916-23925.
192. Sadir R, Baleux F, Grosdidier A, Imberty A, and Lortat-Jacob H: Characterization of the stromal cell-derived factor-1alpha-heparin complex. J Biol Chem 2001;276:8288-8296.
193. Proudfoot AE, Fritchley S, Borlat F, et al.: The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001;276:10620-10626.
194. Martin L, Blanpain C, Garnier P, et al.: Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 2001;40:6303-6318.
195. Yonezawa A, Hori T, Takaori-Kondo A, Morita R, and Uchiyama T: Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1. J Virol 2001;75:4258-4267.
196. Wyatt R, Moore J, Accola M, et al.: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69:5723-5733.
197. Patel M, Yanagishita M, Roderiquez G, et al.: Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retroviruses 1993;9:167-174.
198. Kuschert GS, Hoogewerf AJ, Proudfoot AE, et al.: Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry 1998;37:11193-11201.
199. Gao F, Yue L, White AT, et al.: Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 1992;358:495-499.
200. Chen Z, Gettie A, Ho D D, and Marx P A Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. Virology 1998;246:113-124.
201. Sharp PM, Bailes E, Chaudhuri RR, et al.: The origins of acquired immune deficiency syndrome viruses: Where and when? Philos Trans R Soc Lond B Biol Sci 2001;356:867-876.
202. Hahn BH, Shaw GM, De Cock KM, and Sharp PM: AIDS as a zoonosis: scientific and public health implications. Science 2000;287:607-614.
203. + memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med 2004;200:1299-1314.
204. Etemad-Moghadam B, Rhone D, Steenbeke T, et al.: Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol 2001;75:5646-5655.
205. Kunstman KJ, Puffer B, Korber BT, et al.: Structure and function of CC-chemokine receptor 5 homologues derived from representative primate species and subspecies of the taxonomic suborders Prosimii and Anthropoidea. J Virol 2003;77:12310-12318.
206. Martin KA, Wyatt R, Farzan M, et al.: CD4-independent binding of SIV gp120 to rhesus CCR5. Science 1997;278:1470-1473.
207. Edinger AL, Blanpain C, Kunstman KJ, et al.: Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J Virol 1999;73:4062-4073.
208. Owen SM, Ellenberger D, Rayfield M, et al.: Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol 1998;72:5425-5432.
209. Ping LH, Nelson JA, Hoffman IF, et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants. J Virol 1999;73:6271-6281.
210. Morris L, Cilliers T, Bredell H, Phoswa M, and Martin DJ: CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses 2001;17:697-701.
211. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, and Fenyo EM: Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 1999;15:647-653.
212. Abebe A, Demissie D, Goudsmit J, et al.: HTV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Aids 1999;13:1305-1311.
213. Cilliers T, Nhlapo J, Coetzer M, et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003;77:4449-4456.
214. Stebbing J, and Moyle G: The clades of HIV: their origins and clinical significance. AIDS Rev 2003;5:205-213.
215. Johnston ER, Zijenah LS, Mutetwa S, et al.: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003;77:7682-7688.
216. van Harmelen J, Williamson C, Kim B, et al.: Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses 2001;17:1527-1531.
217. Engelbrecht S, de Villiers T, Sampson CC, et al.: Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa. AIDS Res Hum Retroviruses 2001;17:1533-1547.
218. Moore JP, and Nara PL: The role of the V3 loop of gp120 in HIV infection. Aids 1991;5 Suppl 2:521-33.
219. Bolognesi DP: Prospects for prevention of and early intervention against HIV. Jama 1989;261:3007-3013.
220. Gardner MB, Carlson JR, Jennings M, et al.: SIV vaccine protection of rhesus monkeys. Biotechnol Ther 1991;2:9-19.
221. Bonley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human antibodies. J Virol 2004;78:13232-13252.
222. Koch M, Pancera M, Kwong PD, et al.: Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003;313:387-400.
223. Gorny MK, Revesz K, Williams C, et al.: The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 2004;78:2394-2404.
224. Nyambi PN, Gorny MK, Bastiani L, et al.: Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol 1998;72:9384-9391.
225. Herrera C, Spenlehauer C, Fung MS, et al.: Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol 2003;77:1084-1091.
226. Vancott TC, Polonis VR, Loomis LD, et al.: Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995;11:1379-1391.
227. Mascola JR, Snyder SW, Weislow OS, et al.: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:340-348.
228. Connor RI, Korber BT, Graham BS, et al.: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998;72:1552-1576.
229. Cohen J: Public health. AIDS vaccine trial produces disappointment and confusion. Science 2003;299:1290-1291.
230. Burton DR, and Parren PW: Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? Nat Med 2000;6:123-125.
231. White-Scharf ME, Potts BJ, Smith LM, et al.: Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 1993;192:197-206.
232. Bizebard T, Barbey-Martin C, Fleury D, et al.: Structural studies on viral escape from antibody neutralization. Curr Top Microbiol Immunol 2001;260:55-64.
233. Moore JP, Parren PW, and Burton DR: Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 2001;75:5721-5729.
234. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360.
235. Walker BD, and Korber BT: Immune control of HIV: the obstacles of HLA and viral diversity. Nat Immunol 2001;2:473-475.